Vir Biotechnology Appoints David Liu as Chief Medical Officer

Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology

“David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expertise in global regulatory strategy and execution”

Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology

“I look forward to partnering with him as we advance our Phase 3 program for chronic hepatitis delta and our pipeline of differentiated cancer immunotherapies, and to help us further explore the full potential of our capabilities and technology.”

David Liu, Executive Vice President and Chief Medical Officer of Vir Biotechnology

“Vir Biotechnology is on the forefront of developing next-generation cancer immunotherapies leveraging its expertise in antibody and T-cell engager design, and its novel masking technology.”

David Liu, Executive Vice President and Chief Medical Officer of Vir Biotechnology

“I'm looking forward to building on the work this team has done particularly as the company enters an important period of execution across its programs”

David Liu, Executive Vice President and Chief Medical Officer of Vir Biotechnology

“We have a significant opportunity ahead of us to advance potentially practice-changing therapies that could truly improve outcomes for patients.”